

Wei-Li Kuan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2525429/publications.pdf>

Version: 2024-02-01

27
papers

1,101
citations

516710

16
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

2032
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology. <i>Annals of Neurology</i> , 2015, 78, 160-177.	5.3	204
2	Intracellular SERS Nanoprobes For Distinction Of Different Neuronal Cell Types. <i>Nano Letters</i> , 2013, 13, 2463-2470.	9.1	140
3	A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial Complex I activity. <i>Journal of Experimental Medicine</i> , 2012, 209, 1-10.	8.5	105
4	Characterization and Visualization of Vesicles in the Endo-Lysosomal Pathway with Surface-Enhanced Raman Spectroscopy and Chemometrics. <i>ACS Nano</i> , 2016, 10, 307-316.	14.6	84
5	Gold nanoparticles explore cells: Cellular uptake and their use as intracellular probes. <i>Methods</i> , 2014, 68, 354-363.	3.8	62
6	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 473-488.	4.1	58
7	α -Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function. <i>Experimental Neurology</i> , 2016, 285, 72-81.	4.1	51
8	GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. <i>Nature Communications</i> , 2021, 12, 6666.	12.8	42
9	The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. <i>Psychopharmacology</i> , 2008, 197, 279-293.	3.1	40
10	Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease. <i>Chemical Science</i> , 2020, 11, 525-533.	7.4	35
11	The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. <i>Neurobiology of Disease</i> , 2007, 25, 594-608.	4.4	33
12	Graft-Induced Dyskinesias in Parkinson's Disease: What Is It All About?. <i>Cell Stem Cell</i> , 2010, 7, 148-149.	11.1	32
13	A blueprint for translational regenerative medicine. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	24
14	Systemic α -synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease. <i>Molecular Psychiatry</i> , 2021, 26, 556-567.	7.9	24
15	New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants. <i>Neurorehabilitation and Neural Repair</i> , 2005, 19, 155-181.	2.9	21
16	Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 622-630.	1.9	18
17	The future of cell therapies in the treatment of Parkinson's disease. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1487-1498.	3.1	17
18	A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein. <i>Chemical Science</i> , 2020, 11, 4773-4778.	7.4	16

#	ARTICLE	IF	CITATIONS
19	Modelling the natural history of Huntington's disease progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1143-1149.	1.9	15
20	DJ-1 can form β -sheet structured aggregates that co-localize with pathological amyloid deposits. <i>Neurobiology of Disease</i> , 2020, 134, 104629.	4.4	13
21	Therapeutic Potential of Astrocyte Transplantation. <i>Cell Transplantation</i> , 2022, 31, 096368972211054.	2.5	13
22	Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system. <i>European Journal of Neuroscience</i> , 2016, 44, 2396-2403.	2.6	12
23	Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease. <i>Xenotransplantation</i> , 2006, 13, 233-247.	2.8	11
24	The human cytomegalovirus non-coding Beta2.7 RNA as a novel therapeutic for Parkinson's disease – Translational research with no translation. <i>Virus Research</i> , 2016, 212, 64-69.	2.2	11
25	Early functional changes associated with alpha-synuclein proteinopathy in engineered human neural networks. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C1141-C1152.	4.6	9
26	Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. <i>F1000Research</i> , 2017, 6, 1751.	1.6	8
27	Transvascular delivery of β -synuclein preformed fibrils, using the RVG9R delivery system, generates β -synuclein pathology in the duodenal myenteric plexus of non-transgenic rats. <i>Molecular Psychiatry</i> , 2021, 26, 365-365.	7.9	1